Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2005;36:1071-1076
Published online before print April 21, 2005, doi: 10.1161/01.STR.0000163083.59201.34
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
36/5/1071    most recent
01.STR.0000163083.59201.34v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mishima, K.
Right arrow Articles by Fujiwara, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mishima, K.
Right arrow Articles by Fujiwara, M.
Related Collections
Right arrow Acute Cerebral Infarction

(Stroke. 2005;36:1071.)
© 2005 American Heart Association, Inc.


Original Contributions

Cannabidiol Prevents Cerebral Infarction Via a Serotonergic 5-Hydroxytryptamine1A Receptor–Dependent Mechanism

Kenichi Mishima, PhD; Kazuhide Hayakawa; Kohji Abe, PhD; Tomoaki Ikeda, PhD, MD; Nobuaki Egashira, PhD; Katsunori Iwasaki, PhD Michihiro Fujiwara, PhD

From the Department of Neuropharmacology (K.M., K.H., N.E., K.I., M.F.), Faculty of Pharmaceutical Sciences, and Advanced Materials Institute (K.I., M.F.), Fukuoka University, Japan; Department of Obstetrics and Gynecology (T.I.), Miyazaki Medical College, University of Miyazaki, Japan; Department of Medical Physics (K.A.), School of Allied Health Sciences, Faculty of Medicine, Osaka University, Japan; and Department of Drug Safety Evaluation (K.A.), Developmental Research Laboratories, Shionogi and Co, Ltd, Osaka, Japan.

Reprint requests to Michihiro Fujiwara, PhD, Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma 8-19-1, Fukuoka City, Fukuoka, 814-0180 Japan. E-mail mfuji{at}fukuoka-u.ac.jp

Background and Purpose— Cannabidiol has been reported to be a neuroprotectant, but the neuroprotective mechanism of cannabidiol remains unclear. We studied the neuroprotective mechanism of cannabidiol in 4-hour middle cerebral artery (MCA) occlusion mice.

Methods— Male MCA occluded mice were treated with cannabidiol, abnormal cannabidiol, anandamide, methanandamide, cannabidiol plus capsazepine, and cannabidiol plus WAY100135 before and 3 hours after MCA occlusion. The infarct size was determined after 24 hours (2,3,5-triphenyltetrazolium chloride staining). Cerebral blood flow (CBF) was measured at, before and 1, 2, 3, and 4 hours after MCA occlusion.

Results— Cannabidiol significantly reduced the infarct volume induced by MCA occlusion in a bell-shaped curve. Similarly, abnormal cannabidiol but not anandamide or methanandamide reduced the infarct volume. Moreover, the neuroprotective effect of cannabidiol was inhibited by WAY100135, a serotonin 5-hydroxytriptamine1A (5-HT1A) receptor antagonist but not capsazepine a vanilloid receptor antagonist. Cannabidiol increased CBF to the cortex, and the CBF was partly inhibited by WAY100135 in mice subjected to MCA occlusion.

Conclusions— Cannabidiol and abnormal cannabidiol reduced the infarct volume. Furthermore, the neuroprotective effect of cannabidiol was inhibited by WAY100135 but not capsazepine, and the CBF increased by cannabidiol was partially reversed by WAY100135. These results suggested that the neuroprotective effect of cannabidiol may be related to the increase in CBF through the serotonergic 5-HT1A receptor.


Key Words: cannabidiol • cerebral infarction • middle cerebral artery • serontonin receptor • 5HT1A




This article has been cited by other articles:


Home page
StrokeHome page
K. Hayakawa, K. Mishima, M. Nozako, M. Hazekawa, S. Mishima, M. Fujioka, K. Orito, N. Egashira, K. Iwasaki, and M. Fujiwara
Delayed Treatment With Minocycline Ameliorates Neurologic Impairment Through Activated Microglia Expressing a High-Mobility Group Box1-Inhibiting Mechanism
Stroke, March 1, 2008; 39(3): 951 - 958.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
K. Le Minh, K. Klemm, K. Abshagen, C. Eipel, M. D. Menger, and B. Vollmar
Attenuation of Inflammation and Apoptosis by Pre- and Posttreatment of Darbepoetin-{alpha} in Acute Liver Failure of Mice
Am. J. Pathol., June 1, 2007; 170(6): 1954 - 1963.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. Lindenblatt, M. D. Menger, E. Klar, and B. Vollmar
Darbepoetin-Alpha Does Not Promote Microvascular Thrombus Formation in Mice: Role of eNOS-Dependent Protection Through Platelet and Endothelial Cell Deactivation
Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1191 - 1198.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. A. Andrabi, N. S. Kim, S.-W. Yu, H. Wang, D. W. Koh, M. Sasaki, J. A. Klaus, T. Otsuka, Z. Zhang, R. C. Koehler, et al.
Poly(ADP-ribose) (PAR) polymer is a death signal
PNAS, November 28, 2006; 103(48): 18308 - 18313.
[Abstract] [Full Text] [PDF]